Literature DB >> 24656814

Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer's disease.

Natalia Salvadores1, Mohammad Shahnawaz1, Elio Scarpini2, Fabrizio Tagliavini3, Claudio Soto4.   

Abstract

Alzheimer's disease (AD) diagnosis is hampered by the lack of early, sensitive, and objective laboratory tests. We describe a sensitive method for biochemical diagnosis of AD based on specific detection of misfolded Aβ oligomers, which play a central role in AD pathogenesis. The protein misfolding cyclic amplification assay (Aβ-PMCA), exploits the functional property of Aβ oligomers to seed the polymerization of monomeric Aβ. Aβ-PMCA allowed detection of as little as 3 fmol of Aβ oligomers. Most importantly, using cerebrospinal fluid, we were able to distinguish AD patients from control individuals affected by a variety of other neurodegenerative disorders or nondegenerative neurological diseases with overall sensitivity of 90% and specificity of 92%. These findings provide the proof-of-principle basis for developing a highly sensitive and specific biochemical test for AD diagnosis.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24656814     DOI: 10.1016/j.celrep.2014.02.031

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  65 in total

1.  4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Authors:  Eri Saijo; Michael A Metrick; Shunsuke Koga; Piero Parchi; Irene Litvan; Salvatore Spina; Adam Boxer; Julio C Rojas; Douglas Galasko; Allison Kraus; Marcello Rossi; Kathy Newell; Gianluigi Zanusso; Lea T Grinberg; William W Seeley; Bernardino Ghetti; Dennis W Dickson; Byron Caughey
Journal:  Acta Neuropathol       Date:  2019-10-16       Impact factor: 17.088

Review 2.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

3.  The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases.

Authors:  Matthias Schmitz; Maria Cramm; Franc Llorens; Dominik Müller-Cramm; Steven Collins; Ryuichiro Atarashi; Katsuya Satoh; Christina D Orrù; Bradley R Groveman; Saima Zafar; Walter J Schulz-Schaeffer; Byron Caughey; Inga Zerr
Journal:  Nat Protoc       Date:  2016-10-13       Impact factor: 13.491

4.  Proteopathic tau seeding predicts tauopathy in vivo.

Authors:  Brandon B Holmes; Jennifer L Furman; Thomas E Mahan; Tritia R Yamasaki; Hilda Mirbaha; William C Eades; Larisa Belaygorod; Nigel J Cairns; David M Holtzman; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-26       Impact factor: 11.205

Review 5.  Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Niccolò Candelise; Salvador Ventura; Franc Llorens; Inga Zerr
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

Review 6.  Formation and properties of amyloid fibrils of prion protein.

Authors:  Kei-Ichi Yamaguchi; Kazuo Kuwata
Journal:  Biophys Rev       Date:  2017-12-04

7.  Design, implementation, and interpretation of amplification studies for prion detection.

Authors:  Nicholas J Haley; Jürgen A Richt; Kristen A Davenport; Davin M Henderson; Edward A Hoover; Matteo Manca; Byron Caughey; Douglas Marthaler; Jason Bartz; Sabine Gilch
Journal:  Prion       Date:  2018-03-09       Impact factor: 3.931

8.  An aptamer based fluorometric assay for amyloid-β oligomers using a metal-organic framework of type Ru@MIL-101(Al) and enzyme-assisted recycling.

Authors:  Hong-Xia Ren; Yang-Bao Miao; Yuandong Zhang
Journal:  Mikrochim Acta       Date:  2020-01-09       Impact factor: 5.833

9.  Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides.

Authors:  Greg Goldblatt; Jason O Matos; Jeremy Gornto; Suren A Tatulian
Journal:  Phys Chem Chem Phys       Date:  2015-12-28       Impact factor: 3.676

10.  Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Authors:  Stephanie M Williams; Philip Schulz; Michael R Sierks
Journal:  Eur J Neurosci       Date:  2015-10-15       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.